Open Access<p>Activation of GPR40 Suppresses AGE-Induced Reduction of Type II Collagen and Aggrecan in Human SW1353 Chondrocytes</p>
Author(s) -
Jiaxiang Gu,
Hongsheng Lin,
Yiyuan Zhang,
Tao Xu,
Tianliang Wang,
Xiawei Xue,
Wenzhong Zhang,
Hongjun Liu
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s239273
Subject(s) - aggrecan , type ii collagen , adamts , free fatty acid receptor 1 , extracellular matrix , chemistry , osteoarthritis , western blot , agonist , thrombospondin , receptor , matrix metalloproteinase , medicine , microbiology and biotechnology , endocrinology , biochemistry , biology , pathology , arthritis , metalloproteinase , gene , alternative medicine , articular cartilage
Osteoarthritis (OA) is an age-related chronic degenerative disease. Accumulation of advanced glycation end products (AGEs) induces degradation of the articular extracellular matrix (ECM) and is considered a critical step toward the development and progression of OA. GPR40 is a well-known free fatty acid receptor, which possesses pleiotropic effects in different types of diseases. However, the biological function of GPR40 in OA is indistinct. The purpose of the present study was to determine the impact of the GPR40 agonist GW9508 on AGEs-treated chondrocytes.